SNORD3A: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD3A

NCBI ID: G780851

SNORD3A

Other Name(s): small nucleolar RNA, C/D box 3A | Small nucleolar RNA, C/D box 3A | U3 | RNU3

SNORD3A: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to interact with microRNA (miRNA), a short interfering RNA molecule that can target specific mRNAs for degradation. The C/D box 3A (SNORD3A) is a specific snRNA molecule that has been identified as a potential drug target and biomarker.

The C/D box 3A is a 24-nt RNA molecule that is located within the kilenatal RNA gene (KRG) in the 5'-end of the coding region. It is one of the smaller snRNAs that have been identified in the human genome, with a length of approximately 190 nucleotides. The C/D box 3A gene is located on chromosome 6 and has a proteinase 3 (PR3) domain that is similar to other snRNA genes.

Recent studies have identified the C/D box 3A gene as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The reason for its potential as a drug target is its involvement in the regulation of gene expression and the control of cellular processes that are associated with the disease.

One of the key functions of the C/D box 3A gene is its role in the regulation of microRNA (miRNA) expression. miRNA are short interfering RNA molecules that play a critical role in the regulation of gene expression by binding to specific mRNAs. The C/D box 3A gene has been shown to be involved in the regulation of miRNA expression by binding to the miRNA molecule and preventing its degradation.

In addition to its role in the regulation of miRNA expression, the C/D box 3A gene has also been shown to be involved in the regulation of other cellular processes that are associated with various diseases. For example, studies have shown that the C/D box 3A gene is involved in the regulation of cell adhesion, a critical process that is involved in the development and progression of many diseases, including cancer.

The C/D box 3A gene has also been shown to be involved in the regulation of DNA replication, a critical process that is involved in the development and progression of cancer. Studies have shown that the C/D box 3A gene is involved in the regulation of the DNA replication machinery and that its expression is regulated by various factors, including miRNA.

The potential drug target status of the C/D box 3A gene has led to a growing interest in its potential as a biomarker for various diseases. Studies have shown that the C/D box 3A gene is expressed in various tissues and cells and that its expression is regulated by various factors, including miRNA, DNA methylation, and histone modifications.

In addition to its potential as a drug target and biomarker, the C/D box 3A gene has also been shown to have potential therapeutic applications in the treatment of various diseases. For example, studies have shown that inhibiting the expression of the C/D box 3A gene has the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, the C/D box 3A gene is a potential drug target and biomarker for various diseases. Its involvement in the regulation of microRNA and cellular processes that are associated with disease makes it an attractive target for therapeutic intervention. Further research is needed to fully understand the potential therapeutic applications of the C/D box 3A gene and to develop effective treatments for various diseases.

Protein Name: Small Nucleolar RNA, C/D Box 3A

The "SNORD3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets